Senseonics Eversense

By Laura Lovett August 9, 2018
Not two months after getting the FDA nod for its implantable CGM, Eversense, Senseonics held its Q2 earnings call reporting a increase in year over year revenues. However, it continues to operate at a net loss. “In a matter of just six short weeks, we’ve accomplished a lot. We’ve received the authorization from the agency to commercialize in the US, we launched our US commercial activities...
By Jonah Comstock March 3, 2017
Implantable longterm continuous glucose monitor company Senseonics is in a better place than its financials would suggest. The company posted a net loss of $9.9 million last quarter, up from an $8.4 million loss in the year prior, and is planning to borrow about $5 million from the Oxford Silicon Valley Bank that it’s already $20 million in debt to. But Senseonic’s potentially game-changing...